Genprex adds pharma veteran John Bonfiglio to board

Genprex Inc (NASDAQ:GNPX) announced Tuesday the appointment of Dr John N. Bonfiglio Ph.D. to its board of directors.

Bonfiglio brings more than 30 years of experience in the pharmaceutical and biotech industries, starting as a scientist at Allergan PLC (NYSE:AGN) and holding executive roles at Peregrine Pharmaceuticals Inc, Cypress Bioscience Inc, The Immune Response Corporation and Argos Therapeutics Inc, among others.

Most recently, Bonfiglio served as CEO of Oragenics Inc (NYSEAMERICAN:OGEN) and then played a key role in TapImmune Inc’s merger with Marker Therapeutics Inc (NASDAQ:MRKR).

READ: Eli Lilly’s $8B bet on Loxo is a ‘vote of confidence’ for novel scientific approaches that use DNA to treat cancer

“In my opinion, Genprex’s clinical and pre-clinical research show that its lead drug candidate, Oncoprex™ immunogene therapy, can potentially work synergistically in combination with targeted therapies and immunotherapies to treat cancer patients outside of the population normally targeted by these cancer therapies,” said Bonfiglio in a statement. “Clinical exploration of these areas could lead to market expansion and to new patient populations with unmet medical needs. The market potential for these new combination therapies is very attractive.”

Photo: Business Wire

Bonfiglio has helped raise more than $150 million while helping companies re-list and uplist to national securities exchanges, and he recently joined the board of GT Biopharma Inc.

“We are excited that Dr. Bonfiglio has accepted our invitation to join our board of directors,” said Genprex Chairman and CEO Rodney Varner in a statement. “His experience and expertise are impressive. His background with other biotechnology companies will provide us with extensive knowledge and resources.”

Shares of the Austin, Texas, gene-therapy company recently traded at $1.53 on Nasdaq.

Contact Paul Curcio at [email protected]

Follow him on Twitter @GoCurcioGo

Story by ProactiveInvestors